The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Myositis AutoantibodiesTriggered by Statins

Myositis AutoantibodiesTriggered by Statins

July 14, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Further research revealed the presence of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the pharmacologic target of statins. Patients with this autoantibody were weak and had an elevated CK and appeared to represent a subgroup of necrotizing myopathy (NM). Moreover, the majority of patients had been exposed to statin prior to the onset of weakness. All of the patients responded to immunosuppressant therapy, and many relapsed when the immunosuppressant therapy was terminated. Taken together, the data suggested that the autoantibody to HMGCR was driving statin-associated NM.

You Might Also Like
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Managing Myositis in 3 Different Scenarios
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies
Explore This Issue
July 2017
Also By This Author
  • Exercise Therapy May Take the ‘Tired’ Out of Chronic Fatigue Syndrome

Dr. Oddis then circled back to his patient and found that she was, indeed, positive for the anti-HMGCR autoantibody. Her weakness progressed over time, and at that point in the case history, she had a CK of 6367. Dr. Oddis increased her prednisone and added methotrexate. He then decreased prednisone and added Imuran/methotrexate. A month later, he added intravenous immunoglobulin (IVIG), and two months later, he saw that not only had her muscle weakness clearly improved, but she had her first normal CK reading. When her strength returned, he tapered her IVIG, but did not take her off of it completely. He discontinued Imuran and prednisone. He noted that she has been maintained on that regimen for five years, and although her CK levels have increased over time and remain elevated, her strength is acceptable and her health can be managed on methotrexate and IVIG.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Conclusion

Dr. Oddis concluded his presentation by calling on rheumatologists to recognize the clusters of symptoms that may reflect an autoantibody-associated systemic auto­immune rheumatic disease. These auto­antibodies may accompany statin use, or they may be associated with lung disease. In particular, he drew the audience’s attention to the possibility of autoimmune interstitial lung disease contributing to systemic disease.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Meeting Reports, Soft Tissue Pain Tagged With: 2017 State of the Art Clinical Symposium, AC&R, American College of Rheumatology, dermatomyositis, Diagnosis, muscle, myositis, Pain, patient care, polymyositis, Research, rheumatologist, rheumatology, Statin, Treatment, weaknessIssue: July 2017

You Might Also Like:
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Managing Myositis in 3 Different Scenarios
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies
  • Tips for Myositis Management

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.